On the close of operation on June 30, 2008, the Fund has reported Net Asset Value (NAV) of Tk. 29.52 per unit at current market price basis and Tk. 22.01 at cost price basis against face value of Tk. 10.00 whereas Net Assets of the Fund stood at Tk. 50,18,15,505.00.
Read more...On the close of operation on June 30, 2008, the Fund has reported Net Asset Value (NAV) of Tk. 2.72 per unit at current market price basis and Tk. 2.15 at cost price basis against face value of Tk. 1.00 whereas Net Assets of the Fund stood at Tk. 45,66,56,536.00.
Read more...The company has informed that in accordance with the clause 30 of the Listing Regulations of DSE, a meeting of the Board of Directors of the Company scheduled to be held on 21.07.08 at 10:30 AM in regard to consider its accounts for the year ended 31.03.08, appropriation of profits and about 42nd AGM of the shareholders.
Read more...Unusual times call for unusual measures ... and I think a bear market qualifies as unusual times.
In a bullish or even neutral environment, basic fundamental analysis can help you find solid opportunities. In a bear market though, the rules change. Undervalued stocks can become more undervalued, as the falling tide pulls down even the best of equities. Logical or fair? No, and no. However, that doesn't change the fact that a long-only investor loses money if one or more of their stocks sink.
I suggest an alternative approach in a rough market…one that may be a little unusual, though certainly simple. Rather than starting a search for undervalued companies, why not start your search by finding stocks that are actually moving higher?
I know, I know…it sounds like I've crossed over into the world of technical analysis. Well, maybe a little, but for a good reason. I can cross back into the fundamental world though, by further narrowing the field to just those companies with solid fundamentals. The result is the best of both schools of thought. (To learn how this method can help investors increase profits, check out Blending Technical And Fundamental Analysis.)
If you'd still rather let someone do the digging for you, no problem. I've narrowed a short list of rising stocks into an even shorter list of four stocks, simply by eliminating any tickers of poorly-performing companies. Here are the survivors:
Family Dollar Stores
Some recent retail sales reports have been disappointing; J.C. Penney (NYSE:JCP), Dillard's (NYSE:DDS) and Nordstrom (NYSE:JWN) all struggled in June. Value retailers, however, have actually thrived on being able to cater to money-conscious consumers. Take Family Dollar Stores (NYSE:FDO) as an example. In June, same store sales were up 8%, and total monthly revenue was up 10.7%. The stock hit new highs for the year this week, and has gained 8.7% since early May.
ViroPharma
If we're truly in a bear market, you sure wouldn't know it by looking at shares of ViroPharma (Nasdaq:VPHM). The stock is up 42.9% year-to-date. However, there's still plenty of room between the current price of $11.98 and last year's high around $18.
What gives? Since ViroPharma is a one-trick pony, err, one-drug company, the market's concern has been that a generic pharma company could develop the equivalent of ViroPharma's antibiotic Vancocin. The patent expired years ago. More recently, though, Vancocin worries have been eased. It's now believed the FDA will require any similar drug to be proven to act as the equivalent to Vancocin and not just perform comparably to it.
The market doesn't seem to think that's likely to happen anytime soon. (To learn how to find healthy drug companies, read Measuring The Medicine Makers.)
Rent-a-Center
Although the 4% gain over the last two months isn't exactly stellar, Rent-a-Center's (Nasdaq:RCII) performance helps sweeten the pot. The company swung to a loss in calendar Q4 of last year, but got back in the black in Q1 of this year, and investors have slowly trickled back into the stock.
Rent-a-Center is the second largest rent-to-own outfit in the United States. The common theory is that the credit crisis and slowing economy have been a blessing for companies like Rent-a-Center. Consumers who can't afford to buy outright should be flocking to these rental-to-own alternatives. After a disappointing 2007, there's lots of room for improvement. That's the attraction.
The9 Limited
Although it's up by 21.4% in the just the last two months, The9 Limited (Nasdaq:NCTY) is still well under July's peak around $35.00, which leaves plenty more room for recovery. The current price is about $25.60.
You may not know the company, but odds are you know something about what it does do. Perhaps you've heard of a little 10-million-subscriber online adventure game called "World of Warcraft"? The9 Limited is licensed to operate the subscription-based sensation to Chinese gamers. The company's growth rate has been tremendous. Earnings are up by 35.7% on a YOY basis, and revenue is up 62.7%, also on a YOY basis. The upcoming addition of online game "Audition 2", and the World of Warcraft expansion "Wrath of the Lich King" should further enhance growth.
Parting Thoughts
Do you see any common elements in these four stocks? From my point of view, they're all "distressed economy" beneficiaries, or immune to economic woes including The9 Limited.
Even if you're not a fan of these particular stocks, I think you'll find comparable strength in each of their particular industries. More importantly, I think you're more apt to find rising stocks in each of their industries. And that really is the point, isn't it?
The Dow Jones U.S. Biotech Index recently closed at the best level of 2008 as the Dow Jones Industrial Average traded at a new yearly low. The relative strength shown by the biotech stocks makes this a sector that investors should be focusing on for the second half of the year.
Stock Selection
The issue that many investors have with investing in biotech stocks is the great disparity between the top and bottom performers in the sector. For example, through the first six months of 2008 the top performing biotech stock in the Nasdaq Biotech Index was Idenix Pharmaceuticals (Nasdaq:IDIX), which rose 169%. The stock on the opposite end of the spectrum was Genitope (Nasdaq:GTOP) with its loss of 95%. As you can clearly see the most important aspect of investing in the biotech sector is stock selection.
Next we will examine five biotech stocks that have shown a strong combination of both fundamental and technical qualities. (For more on choosing a stock based on these characteristics, read Blending Technical And Fundamental Analysis.)
The Biotech Watchlist
Genzyme Corporation (Nasdaq:GENZ)
Genzyme is one of the larger biotech firms in the world. The company's No.1 product is a treatment for a rare disorder called Gaucher's disease. The drug, Cerezyme, generated revenue of $1.13 billion in 2007, nearly double the next largest selling drug, Renagel. Some of its drugs in the pipeline that are promising focus on stem cell transplant and multiple sclerosis. Technically, the stock has been in a solid uptrend since bottoming out in 2002 and recently broke a short-term downtrend and is within 10% of the all-time high of $82 set in January.
Gilead Sciences (Nasdaq:GILD)
Speaking of strong technical setups, for the last 14 years Gilead has remained in a long-term uptrend that continues to move the stock higher through both bull and bear markets. The company is best known for the drug Tamiflu and its host of HIV drugs. In 2007, more than two-thirds of Gilead's sales came from its HIV drugs. Because HIV continues to be a worldwide epidemic, the demand for Gilead drugs should remain high into the future.
Illumina (Nasdaq:ILMN)
Since 2003, Illumina has rivaled Gilead for the best chart of any biotech stock. An increase of nearly 5,000% in five years is not a shabby return. The company is in the business of genetic research, which is one of the areas within biotech that is cutting edge and has a lot of buzz. The beauty of Illumina's business is that it sells equipment to the biotech firms and therefore does not rely on one drug to keep sales growing.
Martek Biosciences (Nasdaq:MATK)
The chart of Martek is quite different from the previous two stocks. After trading in a downtrend for three years, the stock broke out in mid-2007 and has been moving higher ever since. What the company does also differentiates it from other biotech companies. It develops nutritional oils from microalgae and fungi that are then used in everything from vitamins to baby formula. In June, the company reported an 89% increase in second-quarter profit, but also warned the third quarter will see a slowdown. The key is to use the volatility and dips in this type of stock as buying opportunities. (To learn more, check out Understanding Volatility Measurements.)
Savient Pharmaceuticals (Nasdaq:SVNT)
Savient is one of the few companies that can brag it is hitting a new all-time high as the overall market breaks down. The company focuses on two main areas: involuntary weight loss and gout. It only has one drug on the market currently, Oxandrin, used to tread involuntary weight loss from surgery, HIV, or other disorders. Savient's gout drug has received orphan status from the FDA and hopes it will receive full approval later this year.
The Biotech Risk Factor
What investors need to realize about biotech stocks is that many of them will be swayed by the sales or approval of one or two drugs. Because of this reliance on such a narrow product base, it is important to understand the volatility and risk that accompanies investing in biotech stocks.
By Martha Graybow
NEW YORK (Reuters) - Battered by critics who blame them for helping to foment the U.S. subprime mortgage meltdown, credit raters are now trying to fend off lawsuits -- including fraud claims brought by their own shareholders.
Many financial companies, including banks and lenders, have been sued following the housing market bust; but the cases against ratings agencies may be among the most closely watched.
That's because the three biggest agencies -- Moody's Corp (MCO.N: Quote, Profile, Research, Stock Buzz), McGraw-Hill Cos Inc's (MHP.N: Quote, Profile, Research, Stock Buzz) Standard & Poor's division and Fitch Ratings, part of Fimalac SA (LBCP.PA: Quote, Profile, Research, Stock Buzz) -- have drawn fire from some politicians and investors for awarding top marks to subprime-linked securities that later disintegrated. They've also been criticized as being too close to issuers who foot the bill for their ratings.
Based on how prior cases have played out, the plaintiffs could face an uphill battle in court -- and ratings firms say they will vigorously defend themselves against the lawsuits. Plaintiffs lawyers, though, say that their claims are strong and that a government report unveiled this week finding "serious shortcomings" at the raters could bolster their cases.
"No one has really crossed the threshold to try to hold the rating agencies accountable for their faulty ratings," said Christopher Keller, a lawyer at law firm Labaton Sucharow LLP, who represents some of the plaintiffs in a shareholder case against Moody's.
"Without their complicity in this process (of rating mortgage-backed debt pools), most of these securities would never have come to market," he said.
The agencies have agreed to institute some reforms. Last month the three top agencies struck a pact with New York's attorney general to change how they charge fees for reviewing mortgage-backed securities. A separate probe by Connecticut's attorney general is ongoing.
Rating agencies have found themselves in court before. When they were sued by Enron investors for allegedly being too slow to downgrade the energy trader's debt, a federal judge dismissed the claims, saying the ratings analysts deserved the same kinds of First Amendment protections that shield journalists because their work was in essence opinion and not a guarantee. Read more...this is one of blue chip share,after huge fall it's give nice buy signal yesterday,
you can go it 115-130 range
and get out 142>,
if it is break support level then it's go upto 152>
"A Bond is simply an 'IOU' in which an investor agrees to loan money to a company or government in exchange for a predetermined interest rate."
If a business wants to expand, one of its options is to borrow money from individual investors. The company issues bonds at various interest rates and sells them to the public. Investors purchase them with the understanding that the company will pay back their original principal plus any interest that is due by a set date [this is called the "maturity"].
A bondholder is mailed a check from the company at set intervals [for example, every month] until the "loan" is paid off.
The interest a bondholder earns depends on the strength of the corporation. For example, a blue chip is more stable and has a lower risk of defaulting on its debt. When companies such as Exxon Mobile, General Electric, etc., issue bonds, they may only pay 7% interest, while a much less stable start-up pays 10%. A general rule of thumb when investing in bonds is "the higher the interest rate, the riskier the bond."
Who can issue bonds? Governments, municipalities, a variety of institutions, and corporations. "Commercial Paper" is simply referring to bonds issued by companies.
There are many types of bonds, each having different features and characteristics. A few of the most notable are zero coupon and convertible.
you can find more:
http://beginnersinvest.about.com/cs/bondbasics
Imagine that you own a business. If you were to divide that business up into small pieces and sell those pieces, you would essentially have issued stock. Quite simply, stock is ownership in a company.
The money you raise from selling those "pieces" of your business can be used to build new plants and facilities, pay down debt, or acquire another company. A smart owner will keep at least 51% of the stock, which will allow them to retain control of the day to day activities. Any person or institution that owns over a majority of the stock is called the "controlling shareholder". Essentially, this person can do anything they want - right down to firing the CEO.
do you want to start stock business?
are you sure you have enough money?are you sure you have enough time?
do you know securities'low?
if all Q's answer Y.
let start your business
if any Q's answer N-let start reading my blog,
© Blogger template Digi-digi by Ourblogtemplates.com 2008
Back to TOP
